Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Abbott |
---|---|
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00872196 |
The purpose of this study is to evaluate the development of specific viral mutations in response to treatment with ABT-072.
Condition | Intervention | Phase |
---|---|---|
Hepatitis C Virus Infection |
Procedure: Blood sample collection |
Phase II |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Single Group Assignment |
Estimated Enrollment: | 68 |
Study Start Date: | March 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1 - Follow-up Study
This is a follow-up study with no treatment and only samples being collected.
|
Procedure: Blood sample collection
Approximately monthly blood collections through a 48 week time period.
|
This is a follow-up study with no treatment and only samples being collected
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Abbott Laboratories ( Daniel Cohen ) |
Study ID Numbers: | M10-605 |
Study First Received: | March 23, 2009 |
Last Updated: | April 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00872196 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Virus Diseases Hepatitis Liver Diseases |
Digestive System Diseases Hepatitis, Viral, Human Hepatitis C |
Virus Diseases Hepatitis RNA Virus Infections Liver Diseases Digestive System Diseases |
Flaviviridae Infections Hepatitis, Viral, Human Hepatitis C Infection |